Grünenthal Gmbh

This early-phase trial tests the safety and tolerability of a new drug called GRT6019 in 24 healthy men. Participants receive multiple doses over 4 weeks and are monitored for side effects and how the drug moves through the body. The goal is to see if GRT6019 is safe enough to st…

This Phase 3 trial tested an experimental drug called RTX-GRT7039, given as an injection into the knee joint, to see if it reduces pain from osteoarthritis. 469 adults with knee osteoarthritis who did not get enough relief from standard treatments took part. The study compared th…

This Phase 3 trial tested whether a single injection of RTX-GRT7039 into the knee can reduce pain in adults with knee osteoarthritis who haven't gotten enough relief from standard treatments. 466 participants received either the drug or a placebo injection. The study measured pai…

This phase 3 trial tested the safety of an experimental drug called RTX-GRT7039, given as a knee injection to 714 adults with moderate to severe osteoarthritis pain that wasn't helped by standard treatments. The study focused on side effects and did not measure how well the drug …

This early-stage study gives 10 healthy men a single dose of GRT6019 with a radioactive tracer to see how the drug is broken down and eliminated. Researchers will measure radioactivity in urine and stool to understand the drug's metabolism. The study does not aim to treat any con…

This early-stage trial tested a single dose of the study drug GRT6019 in 18 healthy men to check its safety and how the body processes it. The study also looked at whether food changes drug absorption. Results will guide future research for Duchenne muscular dystrophy, but this t…